Skip Navigation
Search Menu
Find a Doctor


Photo of Dr. Elizabeth Jaffee

Elizabeth Marion Jaffee, M.D.

Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Professor of Oncology


Appointment Phone


Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • The Dana and Albert "Cubby" Broccoli Professor of Oncology
  • Co-Director, Skip Viragh Center for Pancreas Cancer
  • Co-Director, Gastrtointestinal Cancers Program
  • Co-Director of the Cancer Immunology Program and the Immunology and Hematopoiesis Division
  • Professor of Oncology
  • Professor of Pathology

Centers & Institutes


  • Oncology - Gastrointestinal Cancer
  • Pathology


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-2957

Contact for Research Inquiries

Cancer Research Building
1650 Orleans Street
Baltimore, MD 21231 map
Phone: 410-955-2957
Fax: 410-614-8216


Medical Oncology, Pancreatic Cancer

Research Interests

Vaccine therapies for solid tumors; Mechanisms of induction of mouse and human antitumor immune responses


After graduating Magna cum laude from Brandeis University, Dr. Jaffee received her M.D. from New York Medical College. She completed her internship and residency at University of Pittsburgh, Presbyterian-University Hospital, then received NIH Research funding as a Research Fellow at the University of Pittsburgh under the guidance of Fran Finn, Ph.D., Research Director. Dr. Jaffee subsequently completed a three Medical Oncology postdoctoral fellowship came at The Johns Hopkins University School of Medicine in Baltimore, M.D. In 1992, Dr. Jaffee was appointed Assistant Professor of Oncology at the Johns Hopkins University School of Medicine (JHUSOM), as well as Medical Director of the Johns Hopkins Oncology Center Cell Processing and Gene Therapy Facility. In 1995, Dr. Jaffee was appointed to a faculty position in the Graduate Program in Immunology. She currently holds faculty positions in the Graduate Program in Pharmacology, the Graduate Program of Cell and Molecular Medicine, and the Graduate Program in Immunology. She was promoted to Associate Professor in 1997, and to Professor of Oncology in 2002. She is the first recipient of the Dana and Albert Cubby Broccoli Professor of Oncology. Dr. Jaffee has focused her scientific career on the pre-clinical and clinical development of vaccines for the treatment of cancer. Dr. Jaffee has published over 100 peer reviewed papers and more than 30 invited reviews, commentaries or book chapters in this area of research.

Dr. Jaffee currently serves as the Co-Director of the Division of Immunology, and Co-leader of the Gastrointestinal Cancers Program in the Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She is also the Associate Director for Translational Research at the Sidney Kimmel Cancer Center at Johns Hopkins. She established and directs the Johns Hopkins Oncology Center Cell Processing and Gene Therapy cGMP Facility. In 2007, she was appointed a Deputy Director for the Institute for Translational and Clinical Research at JHUSOM. Her role is to develop translational programs and Core Resources to facilitate moving novel concepts into first in man clinical testing. She previously served as Chair of the Clinical Research Committee at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and served a 4-year term on the NCI Tumor Immunology study section and another 4-year term on the NCI Parent Sub-committee D. Dr. Jaffee is currently serving a 5-year term as a member of the NCI Board of Scientific Counselors, and is also a member of the RAID NCI Program Oversight Committee. Her professional society service has included membership in AACR since 1992 where she has served on a number of program committees and a three-year term on the Women in Cancer Research (WICR) Board. She has been a member of ASCO since 1992 and currently serves on the ASCO grants selection committee. Dr. Jaffee serves on a number of External advisory boards for other cancer centers. She has mentored 21 post-doctoral fellows and 12 graduate students, many of which hold Assistant, Associate, and Professor titles at other leading Universities. Dr. Jaffee holds 6 vaccine patents, has been the Laboratory Principal Investigator on 11 Clinical Studies for which she has been elucidating the immunologic responses to vaccine therapies in patients with pancreatic and breast cancers. more

    Additional Information

  • Education +


    • New York Medical College / MD (1985)


    • Presbyterian University Hospital/UPMC / Medicine (1988)


    • Johns Hopkins University School of Medicine / Oncology (1992)


    • American Board of Internal Medicine / Internal Medicine (1988)
  • Research & Publications +

    Research Summary

    Dr. Jaffee's laboratory has two main areas of on-going research. The first area focuses on developing vaccines strategies that augment antitumor immune responses. Our group has extensive experience studying murine antitumor immune responses that are generated following vaccination with tumor cells genetically altered to secrete cytokines in a paracrine fashion. This strategy is already being translated into clinical trials. More recently, my laboratory is employing a transgeneic mouse models of breast and pancreatic cancers to study the interactions of the tumor micro-environment, the tumor, and the immune reactions that shape the overall tumor miero-environment.

    The second area of research focuses on the evaluation of human immune responses following vaccination in patients. We have now developed a large bank of immunized specimens from multiple clinical trials. We have developed functional genomic and proteomic approaches to identify the immune targets of the vaccine induced immune response. We have identified a number of new proteins that are serving as antigens against which to understand how to induce an effective immune response against cancer in patients. These new proteins are also associated with cancer development and progression, and the development of immune tolerance.

    CORE Facilities

    SKCCC Cell Processing & Gene Therapy

    Clinical Trial Keywords: breast cancer, pancreatic cancer, vaccine

    Selected Publications View all on PubMed

    1. Murata, S.; Ladle, B.H.; Kim, P.S.; Lutz, E.R.; Wolpoe, M.E.; Ivie, S.E.; Smith, H.M.; Armstrong, T.D.; Emens, L.A.; Jaffee, E.M.; Reilly, R.T. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J Immunol. 2006 Jan 15;176(2):974-983.
    2. Couch, M.E.; Ferris, R.L.; Brennan, J.A.; Koch, W.M.; Jaffee, E.M.; Leibowitz, M.S.; Nepom, G.T.; Erlich, H.A.; Sidransky, D. Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin Cancer Res. 2007 Dec 1;13(23):7199-7206.
    3. Lin, K.Y.; Lu, D.; Hung, C.F.; Peng, S.; Huang, L.; Jie, C.; Murillo, F.; Rowley, J.; Tsai, Y.C.; He, L.; Kim, D.J.; Jaffee, E.; Pardoll, D.; Wu, T.C. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res. 2007 Feb 15;67(4):1832-1841.
    4. Manning, E.A.; Ullman, J.G.; Leatherman, J.M.; Asquith, J.M.; Hansen, T.R.; Armstrong, T.D.; Hicklin, D.J.; Jaffee, E.M.; Emens, L.A. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007 Jul 1;13(13):3951-3959.
    5. Pardoll, D. Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. In: Prendergast G, J.E., editor, Cancer Immunotherapy: Immune Suppression and Tumor Growth: Academic Press; 2007. p. 257-276.
    6. Herman, J.M.; Swartz, M.J.; Hsu, C.C.; Winter, J.; Pawlik, T.M.; Sugar, E.; Robinson, R.; Laheru, D.A.; Jaffee, E.; Hruban, R.H.; Campbell, K.A.; Wolfgang, C.L.; Asrari, F.; Donehower, R.; Hidalgo, M.; Diaz, L.A., Jr.; Yeo, C.; Cameron, J.L.; Schulick, R.D.; Abrams, R. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008 Jul 20;26(21):3503-3510.
    7. Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.M.; Fu, B.; Lin, M.T.; Calhoun, E.S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein, A.P.; Jaffee, E.M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801-1806.
    8. Kim, P.S.; Armstrong, T.D.; Song, H.; Wolpoe, M.E.; Weiss, V.; Manning, E.A.; Huang, L.Q.; Murata, S.; Sgouros, G.; Emens, L.A.; Reilly, R.T.; Jaffee, E.M. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest. 2008 May;118(5):1700-1711.
    9. Laheru, D.; Lutz, E.; Burke, J.; Biedrzycki, B.; Solt, S.; Onners, B.; Tartakovsky, I.; Nemunaitis, J.; Le, D.; Sugar, E.; Hege, K.; Jaffee, E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008 Mar 1;14(5):1455-1463.
    10. Le, D.; Jaffee, E.M.; Laheru, D.A. Development of Vaccine Therapy for Pancreas Cancer. In: Andrew Lowy, S.L., Philip Philip, editor. 1 ed, Pancreatic Cancer. New York: Springer; 2008.
    11. Le, D.; Kim, P.; Jaffee, E.M. Current Cancer Therapeutics. In: David Ettinger, R.D., editor, Cancer Vaccines. Philadelphia: Current Medicine, LLC; 2008.
    12. Le, D.T.; Kim, P.S.; Jaffee, E.M. Role of Tolerance in Cancer Immunotherapy. In: Vincent T. Devita, T.S.L., Steven Rosenber, editor, Principles and Practice of Oncology Focus Series. New York: Wolters Kluwer Health; 2008.
    13. Miyashita, T.; Shah, F.A.; Marti, G.; Wang, J.; Armstrong, T.; Bonde, P.; Gibson, M.K.; Yoshimura, K.; Montgomery, E.A.; Duncan, M.D.; Jaffee, E.M.; Harmon, J.W. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. J Gastrointest Surg. 2008 Jan;12(1):2-7; discussion 7-9.
    14. Blackford, A.; Parmigiani, G.; Kensler, T.W.; Wolfgang, C.; Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Eshleman, J.R.; Goggins, M.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Klein, A.; Cameron, J.L.; Olino, K.; Schulick, R.; Winter, J.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W.; Hruban, R.H. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009 Apr 15;69(8):3681-3688.
    15. Blackford, A.; Serrano, O.K.; Wolfgang, C.L.; Parmigiani, G.; Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Eshleman, J.R.; Goggins, M.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Cameron, J.L.; Olino, K.; Schulick, R.; Winter, J.; Herman, J.M.; Laheru, D.; Klein, A.P.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E.; Hruban, R.H. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009 Jul 15;15(14):4674-4679.
    16. Disis, M.L.; Bernhard, H.; Jaffee, E.M. Use of tumour-responsive T cells as cancer treatment. Lancet. 2009 Feb 21;373(9664):673-683.
    17. Emens, L.A.; Asquith, J.M.; Leatherman, J.M.; Kobrin, B.J.; Petrik, S.; Laiko, M.; Levi, J.; Daphtary, M.M.; Biedrzycki, B.; Wolff, A.C.; Stearns, V.; Disis, M.L.; Ye, X.; Piantadosi, S.; Fetting, J.H.; Davidson, N.E.; Jaffee, E.M. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009 Dec 10;27(35):5911-5918.
    18. Jones, S.; Hruban, R.H.; Kamiyama, M.; Borges, M.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Palmisano, E.; Brune, K.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Parmigiani, G.; Kern, S.E.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Eshleman, J.R.; Goggins, M.; Klein, A.P. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009 Apr 10;324(5924):217.
    19. Kitamura, N.; Murata, S.; Ueki, T.; Mekata, E.; Reilly, R.T.; Jaffee, E.M.; Tani, T. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer. 2009 Aug 1;125(3):630-638.
    20. Ferris, R.L.; Jaffee, E.M.; Ferrone, S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010 Oct 1;28(28):4390-4399.
    21. Le, D.T.; Ladle, B.H.; Lee, T.; Weiss, V.; Yao, X.; Leubner, A.; Armstrong, T.D.; Jaffee, E.M. CD8(+)Foxp3(+) tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. Int J Cancer. 2010 Sep 20.
    22. Le, D.T.; Pardoll, D.M.; Jaffee, E.M. Cellular vaccine approaches. Cancer J. 2010 Jul-Aug;16(4):304-310.
    23. Pfannenstiel, L.W.; Lam, S.S.; Emens, L.A.; Jaffee, E.M.; Armstrong, T.D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol. 2010;263(1):79-87.
    24. Wu, H.; Caffo, B.; Jaffee, H.A.; Irizarry, R.A.; Feinberg, A.P. Redefining CpG islands using hidden Markov models. Biostatistics. 2010 Jul;11(3):499-514.
    25. Lutz, E.; Yeo, C.J.; Lillemoe, K.D.; Biedrzycki, B.; Kobrin, B.; Herman, J.; Sugar, E.; Piantadosi, S.; Cameron, J.L.; Solt, S.; Onners, B.; Tartakovsky, I.; Choi, M.; Sharma, R.; Illei, P.B.; Hruban, R.H.; Abrams, R.A.; Le, D.; Jaffee, E.; Laheru, D. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation. Ann Surg. 2011 Jan 6;Epub 1/11/11.
  • Academic Affiliations & Courses +
  • Activities & Honors +


    • National Kidney Cancer Career Development Award
    • Dean's List, Brandeis University, 1977 - 1981
    • Magna cum laude with highest honors in Biology/Immunology, Brandeis University, 1981
    • Clinical Fellow, American Cancer Society, 1989
    • Clinician-Scientist Award, Johns Hopkins School of Medicine, 1992
    • Physician-Scientist Award, NIH, 1992
    • Research Fellowship Award, American Cancer Society, 1992
    • Stetler Award, 1992
    • Young Investigator Award, American Society of Clinical Oncology, 1992
    • Directors Award for Outstanding Teaching, JHU Department of Oncology, 1998
    • Directors Award for Outstanding Teaching, JHU Department of Oncology, 1999
    • Directors Award for Outstanding Teaching, JHU Department of Oncology, 2001
    • Recipient of the Dana and Albert Broccoli Endowed Chair in Oncology, 2002
    • Recipient of the NCI Spore Program Investigator of the year, 2006


    • American Association for Cancer Research
    • American Association for the Advancement of Science
    • American Association of Immunologists
    • American Society of Clinical Oncology
    • International Society of Biological Therapy
  • Videos & Media +
Is This You? Edit Profile